[e-drug] DNDi on access to antimalarial ASAQ at net price

["Ann-Marie Sevcsik" <amsevcsik@dndi.org>]

E-DRUG: DNDi on access to antimalarial ASAQ at net price
-----------------------------------------------------

Information from Sanofi-Aventis and DNDi on how to get access today to ASAQ at a 'No profit-No loss' price

To view this information in PDF, visit http://www.actwithasaq.org/en/ASAQAvailability_ENG_July2007

How to get access today to ASAQ at a 'No profit-No loss' price?

The artesunate plus amodiaquine antimalarial fixed-dose combination (ASAQ) is available as ArteSunate-AmodiaQuine Winthrop for public markets, NGOs and not-for-profit institutions, and under the brand names Coarsucam for the private market or Coarsucam Impact Malaria for 'no profit-no loss' social programs with the private sector.

In many countries, Coarsucam needs to be registered before ArteSunate AmodiaQuine Winthrop can be submitted to national regulatory agencies. 

Until Artesunate Amodiaquine Winthrop is registered, NGOs and other not-for-profit institutions who are interested in obtaining ASAQ can purchase Coarsucam Impact Malaria at a 'no profit-no loss' price under the following conditions:
- Coarsucam Impact Malaria is registered in the country of interest (AMM or authorisation of importation)
- Minimum order of 5000â
- Qualified person ('pharmacien responsable" or 'responsible pharmacist) required
- Storage facility available at country level

Coarsucam Impact Malaria was submitted for registration in 23 sub-Saharan African countries and is registered in the following countries as of 5 July 2007 (this list will be updated regularly).

COUNTRIES: Date of approval
BURKINA FASO: 22 Dec 2006
CAMEROON: 2 July 2007
CENTRAL AFRICAN REPUBLIC: 3 July 2007
CHAD: 8 May 2007
CONGO: 24 Jan 2007
GABON: 30 Nov 2006
GUINEA: 27 Dec 2006
MALI: 17 Feb 2007
DEMOCRATIC REPUBLIC OF CONGO: 25 Jan 2007
GHANA: 27 Apr 2007
KENYA: 30 May 2007
MADAGASCAR: 20 Dec 2006
MAURITANIA: 14 Feb 2007

GMP inspection of the production site in Morocco was carried out by independent experts appointed by Medecins Sans Frontieres. The experts' report confirmed the compliance of ASAQ manufacturing operations with WHO GMP recommendations.

Information regarding the product
- Boxes of 25 blisters
- Product presentation with Summary of Product Characteristics (document available in English and in French) 

Contacts:
Sanofi-Aventis : 
Customer service Tel +33 1 41 24 01 34
Fax: + 33 1 41 24 58 62
francois.desbrandes@sanofi-aventis.com
claude.geant@sanofi-aventis.com
Medical Department: 
valerie.lameyre@sanofi-aventis.com

DNDi: Graciela Diap - gdiap@dndi.org